Mesoblast Net Worth
Mesoblast Net Worth Breakdown | MESO |
Mesoblast Net Worth Analysis
Mesoblast's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mesoblast's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mesoblast's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mesoblast's net worth analysis. One common approach is to calculate Mesoblast's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mesoblast's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mesoblast's net worth. This approach calculates the present value of Mesoblast's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mesoblast's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mesoblast's net worth. This involves comparing Mesoblast's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mesoblast's net worth relative to its peers.
Enterprise Value |
|
To determine if Mesoblast is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mesoblast's net worth research are outlined below:
| Mesoblast had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 17.2 M. Net Loss for the year was (102.14 M) with loss before overhead, payroll, taxes, and interest of (22.74 M). | |
| Mesoblast currently holds about 85.5 M in cash with (49.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
| Latest headline from globenewswire.com: Independent Study Presented at American Society of Hematology Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD |
Mesoblast Quarterly Good Will |
|
Mesoblast uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mesoblast. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mesoblast's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 23rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of September 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Know Mesoblast's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mesoblast is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mesoblast backward and forwards among themselves. Mesoblast's institutional investor refers to the entity that pools money to purchase Mesoblast's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lpl Financial Corp | 2025-06-30 | 50 K | Rockbridge Investment Management, Llc | 2025-06-30 | 49.1 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 40.7 K | Two Sigma Investments Llc | 2025-06-30 | 33.2 K | Millennium Management Llc | 2025-06-30 | 32.3 K | Oasis Management Co. Ltd | 2025-06-30 | 29.5 K | Verition Fund Managegment, Llc | 2025-06-30 | 28.8 K | Citigroup Inc | 2025-06-30 | 25.9 K | Wells Fargo & Co | 2025-06-30 | 25.3 K | Blackrock Inc | 2025-06-30 | 656.8 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 504.4 K |
Follow Mesoblast's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.94 B.Market Cap |
|
Project Mesoblast's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.09) | (0.10) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.17) | (0.18) |
When accessing Mesoblast's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mesoblast's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mesoblast's profitability and make more informed investment decisions.
Evaluate Mesoblast's management efficiency
Mesoblast has return on total asset (ROA) of (0.0537) % which means that it has lost $0.0537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1895) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities. As of the 14th of December 2025, Return On Tangible Assets is likely to drop to -0.5. In addition to that, Return On Capital Employed is likely to drop to -0.1. As of the 14th of December 2025, Non Currrent Assets Other is likely to grow to about 1.7 M, while Total Assets are likely to drop about 596.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.52 | 0.53 | |
| Tangible Book Value Per Share | 0.02 | 0.02 | |
| Enterprise Value Over EBITDA | (16.47) | (17.30) | |
| Price Book Value Ratio | 2.09 | 1.98 | |
| Enterprise Value Multiple | (16.47) | (17.30) | |
| Price Fair Value | 2.09 | 1.98 | |
| Enterprise Value | 1.2 B | 1.2 B |
Leadership at Mesoblast emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 123.2524 | Revenue | Quarterly Revenue Growth 4.586 | Revenue Per Share | Return On Equity |
Mesoblast Corporate Filings
6K | 12th of December 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 16th of September 2025 Other Reports | ViewVerify | |
| 12th of September 2025 Other Reports | ViewVerify | |
| 29th of August 2025 Other Reports | ViewVerify |
Mesoblast Earnings per Share Projection vs Actual
Mesoblast Corporate Management
| LLB BCom | Joint Secretary | Profile | |
| Justin BS | Head Manufacturing | Profile | |
| LLB BSc | General Executive | Profile | |
| Marcelo Santoro | Chief Officer | Profile | |
| Roger BA | Head Disorders | Profile | |
| Fiona See | Senior Research | Profile | |
| MS MBA | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share | Quarterly Revenue Growth 4.586 | Return On Assets | Return On Equity |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.